Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAP Adaptimmune Therapeutics PLC

Market Closed 04-04 16:00:00 EDT

0.2581

-0.0658

-20.31%

盘后0.2600

+0.0019+0.74%

19:59 EDT

High0.3200	Low0.2500	Vol2.02M
Open0.3150	D1 Closing0.3239	Amplitude21.61%
Mkt Cap66.39M	Tradable Cap45.29M	Total Shares257.23M
T/O572.63K	T/O Rate1.15%	Tradable Shares175.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ADAP","market":"US","secType":"STK","nameCN":"Adaptimmune Therapeutics PLC","latestPrice":0.2581,"timestamp":1743796800000,"preClose":0.3239,"halted":0,"volume":2017040,"hourTrading":{"tag":"盘后","latestPrice":0.26,"preClose":0.2581,"latestTime":"19:59 EDT","volume":6978,"amount":1818.489,"timestamp":1743811186415},"delay":0,"floatShares":175463180,"shares":257231941,"eps":-0.3,"marketStatus":"Market Closed","change":-0.0658,"latestTime":"04-04 16:00:00 EDT","open":0.315,"high":0.32,"low":0.25,"amount":572634.9329959999,"amplitude":0.216116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.3,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":1,"adrRate":6,"listingDate":1430884800000,"exchange":"NASDAQ","adjPreClose":0.3239,"preHourTrading":{"tag":"盘前","latestPrice":0.3203,"preClose":0.3239,"latestTime":"09:19 EDT","volume":11921,"amount":3783.97311838,"timestamp":1743772774803},"postHourTrading":{"tag":"盘后","latestPrice":0.26,"preClose":0.2581,"latestTime":"19:59 EDT","volume":6978,"amount":1818.489,"timestamp":1743811186415},"volumeRatio":0.4488598140907142,"impliedVol":1.571,"impliedVolPercentile":0.6414},"requestUrl":"/m/hq/s/ADAP","defaultTab":"news","newsList":[{"id":"2524014307","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524014307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524014307?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:11","pubTimestamp":1743520287,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.From continental Europe,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NCNA","ASND","GNFT","NOK","BK4117","AKTX","LU0109394709.USD","SLN","BK4547","BK4082","AFG","BK7142","LU0320765992.SGD","BK4201","BK4007","EQNR","WPP","BK4585","AUTL","TRIB","DBVT","BK4588","BK4207","BK4107","BK4020","BCYC","BK4521","EVAX","SAN","ADAP","IE00BMPRXN33.USD","BK4009","LU0889565916.HKD","SAN.AU","WPP.AU","BK4139","IE00BMPRXR70.SGD","EDAP"],"gpt_icon":0},{"id":"2524970911","title":"Adaptimmune Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970911","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970911?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:47","pubTimestamp":1743508020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 07:47 ET (11:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP","LENZ"],"gpt_icon":0},{"id":"2524195159","title":"Adaptimmune Therapeutics Plc : H.c. Wainwright Cuts Target Price to $3 From $3.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2524195159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524195159?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:09","pubTimestamp":1743502168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nAZN3N4EAY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522250119","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522250119","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522250119?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:09","pubTimestamp":1743174595,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.49% to 1,404.43 on the S&P Europe Select ADR Index, which is about 1.5% lower for the week.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Genfit , which advanced 49% and 5.2% respectively. They were followed by pharmaceutical company Sanofi , which rose 1.5%.The decliners from continental Europe were led by internet advertising firm Criteo , which fell 3.6%. It was followed by internet browser company Opera  and financial services company Banco Bilbao Vizcaya Argentaria , which were down 3.1% and 2.8% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana  and utilities provider National Grid , which increased 5.6% and 2.9% respectively. They were followed by telecommunications operator Vodafone Group  and biopharmaceutical company Adaptimmune Therapeutics , which were up 2% and 1.6% re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","IE00BFMHRM44.USD","BCS","ADAP","GNFT","NCNA","BK4117","BK4007","NGG","IE00BFXG1179.USD","AMRN","CUK","BK4532","OPRA","BK4521","BK4009","VOD","BK4208","MREO","BK4585","BK4588","BK4107","BBVA","AFG","DBVT","BK4207","SNY","BK4505","BK4132","CRTO","BK4023","BK4139"],"gpt_icon":0},{"id":"2522085309","title":"Barclays Remains a Sell on Adaptimmune Therapeutics (ADAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085309?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:35","pubTimestamp":1743082533,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Sell rating on Adaptimmune Therapeutics (ADAP – Research Report) on March 25 and set a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-adaptimmune-therapeutics-adap?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-adaptimmune-therapeutics-adap?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522802854","title":"Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802854?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:50","pubTimestamp":1742997000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:50 ET (13:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP","LENZ"],"gpt_icon":0},{"id":"2522482154","title":"Adaptimmune Therapeutics Plc : Guggenheim Cuts Target Price to $1.75 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522482154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522482154?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:20","pubTimestamp":1742984409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522006169","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006169?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:08","pubTimestamp":1742915311,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Tuesday morning, up 0.73% to 1,435.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BDRX","BNTX","LU2237443465.HKD","LU2237443549.SGD","ASND","NCNA","LU0084288595.USD","BK4117","AKTX","NTZ","LU2237443382.USD","BK4548","SLN","AFG","LU0320765992.SGD","LU1162221912.USD","ING.AU","LU2237443895.HKD","DAVA","BK4201","BK4007","MREO","BK4134","BK4585","BK7141","DBVT","BK4207","LU0098860793.USD","BK4535","BK4107","LU0300736062.USD","LU2129689431.USD","DAVA.AU","LU2237443978.SGD","LU2129689514.USD","LU0648005311.SGD","TTE","EVAX","ING","ADAP","BK7505","BK4505","BK4551","LU0889565916.HKD","LU0300736492.USD","BK4139","EDAP","LU2129689605.HKD","SHEL","LU2236285917.USD"],"gpt_icon":0},{"id":"2522023527","title":"Adaptimmune Therapeutics (ADAP) Gets a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023527?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:56","pubTimestamp":1742900214,"startTime":"0","endTime":"0","summary":"Scotiabank analyst George Farmer maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $1.40...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAP","BK4139","MMAT","BK4141"],"gpt_icon":0},{"id":"2522072340","title":"ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2522072340","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522072340?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 17:26","pubTimestamp":1742894760,"startTime":"0","endTime":"0","summary":"After the market closed on 3/24/25, Adaptimmune  filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $ per diluted ordinary share versus our $ estimate. Relative to our model, the EPS miss was largely a function of non-recurring restructuring costs of $6.0 million and a $10.4 million impairment loss on leasehold improvement assets related to ADAP’s UK manufacturing facility.From a distribution standpoint, 20 Authorized Treatment Centers  are currently up and running and accepting referrals, with senior executives reiterating expectations to complete the rollout of the full network of 30 ATCs by end of 2025 . Moreover, manufacturing turnaround times have remained quicker than expected thus far, with ample s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adap-4q24-earnings-review-eps-092600329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAP"],"gpt_icon":0},{"id":"2522700076","title":"BRIEF-Adaptimmune Therapeutics PLC - Enters Amendment To Loan And Security Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700076?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:43","pubTimestamp":1742849018,"startTime":"0","endTime":"0","summary":"BRIEF-Adaptimmune Therapeutics PLC - Enters Amendment To Loan And Security Agreement - SEC FilingMarch 24  - Adaptimmune Therapeutics PLC ADAP.O:ADAPTIMMUNE THERAPEUTICS PLC - ENTERS AMENDMENT TO LOAN AND SECURITY AGREEMENT - SEC FILINGADAPTIMMUNE THERAPEUTICS PLC - TO MAKE $25 MILLION LOAN PREPAYMENT - SEC FILINGSource text: [ID:n0001558370-25-003542]Further company coverage: ADAP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2522000487","title":"Adaptimmune Therapeutics Plc - to Make $25 Mln Loan Prepayment - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522000487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522000487?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:42","pubTimestamp":1742848946,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2521610401","title":"Adaptimmune Therapeutics Plc : Scotiabank Cuts Target Price to $1.4 From $3.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2521610401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521610401?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:48","pubTimestamp":1742554107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q40LQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2521424188","title":"Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521424188","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521424188?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 15:01","pubTimestamp":1742540516,"startTime":"0","endTime":"0","summary":"Q4 2024 Product Revenue: $1.2 million from Tecelra sales.Authorized Treatment Centers : 20 ATCs established, representing 2/3 of the planned network.Patient Apheresis in Q1 2025: 10 patients apheresed with 3 more scheduled, totaling 13 anticipated.Expected Q1 2025 Invoicing: 6 to 8 patients, three to four times the prior quarter.Projected 2025 Sales: Approximately $25 million, aligning with analyst forecasts.Manufacturing Performance: 100% of products manufactured to specification with no failures; turnaround time under 30 days.Reimbursement Success: Over 70% of commercial and Medicare lives covered with no denials.Cost Savings: $75 million to $100 million reduction in forward cash flow demands through 2028 by pausing pre-clinical programs.Cash Savings from Restructuring: $300 million over the period announced previously.GuruFocus has detected 6 Warning Signs with ADAP.Adaptimmune Therapeutics PLC  has paused spending on pre-clinical programs targeting PRAME and CD70, which may impact ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-therapeutics-plc-adap-q4-070156398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAP"],"gpt_icon":0},{"id":"2521242901","title":"Adaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2521242901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521242901?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 14:57","pubTimestamp":1742540273,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Repor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-receives-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-receives-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAP","BK4207","MFG"],"gpt_icon":0},{"id":"2521499286","title":"ADRs Close Lower; Adaptimmune Therapeutics PLC Declines 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499286?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:30","pubTimestamp":1742502600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Thursday, as the S&P/BNY Mellon index of American depositary receipts fell 0.4% to 194.80.The European index declined 0.3% to 180.79. The Asian index fell 0.4% to 246.64. The Latin American index dropped 0.9% to 195.13, while the emerging-markets index dropped 0.4% to 392.37.Adaptimmune Therapeutics PLC, based in United Kingdom, posted the largest decline, plummeting 38% to 28 cents, followed by shares of China's Yiren Digital Ltd., which cratered 20% to $6.85. Shares of Israel-based Alarum Technologies Ltd. plunged 18% to $6.61.Hong Kong's Graphex Group Ltd. was the biggest leader during the session, soaring 32% to 32 cents, and Sweden-based NIP Group Inc. rocketed 29% to $2.67. Akari Therapeutics PLC, which is based in United Kingdom, rounded out the top three leaders on Thursday, with shares soaring 20% to $1.50.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2520463019","title":"European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520463019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520463019?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:13","pubTimestamp":1742483595,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.47% to 1,438.05 on the S&P Europe Select ADR Index.From continental Europe, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSO","SAN","BK1610","LU1093756168.USD","LU0540923850.HKD","TRIB","AKTX","CLLS","HSBC","LU0128525689.USD","BDRX","BK7104","LU2236285917.USD","BK4521","CRTO","LU0516423174.USD","BBVA","TCBP","EVAX","LU0348735423.USD","BK4599","LU0310800965.SGD","ERIC","TRVG","BK4007","BK4204","HSHD.SI","NVO.AU","BK4588","ADAP","BK4107","BK4207","BK4591","NCNA","BK4009","BK4585","HSBA.UK","IE00BFMHRM44.USD","LU0149721374.USD","BK4117","SAN.AU","TCBPY","LU1481107354.HKD","BK1601","03143","BK4554","IE00BZ1G4Q59.USD","00005","AFG","BK1572"],"gpt_icon":1},{"id":"2520743010","title":"Adaptimmune Provides Q4 and Full Year 2024 Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520743010","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520743010?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"TECELRA launch momentum accelerating– 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved. Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026. Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs. At the end of 2024, Adaptimmune had Total Liquidity1 of $152 million. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: \"2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is going very well and each step in delivering this important medicine: activating our treatment network; identifying biomarker eligible patients; exceptional manufacturing quality and turn-around times, strengthens our sarcoma platform capabilities for both Tecelra and for lete-cel. These results give us confidence in our strategy to build value from our sarcoma franchise a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-provides-q4-full-2024-110000539.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-provides-q4-full-2024-110000539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4080","ADAP","BK4139","SITC"],"gpt_icon":0},{"id":"2520679695","title":"Adaptimmune Therapeutics PLC  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520679695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520679695?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:58","pubTimestamp":1742302686,"startTime":"0","endTime":"0","summary":"Adaptimmune Therapeutics PLC  expected to post a loss of13cents a share - Earnings Preview Adaptimmune Therapeutics PLC ADAP.OQ ADAP.O is expected to show a rise in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL8N3Q115N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP"],"gpt_icon":0},{"id":"2518772203","title":"Adaptimmune Therapeutics PLC  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772203?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:50","pubTimestamp":1741726214,"startTime":"0","endTime":"0","summary":"Adaptimmune Therapeutics PLC  expected to post a loss of15cents a share - Earnings Preview Adaptimmune Therapeutics PLC ADAP.OQ ADAP.O is expected to show a rise in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU2FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptimmune.com","stockEarnings":[{"period":"1week","weight":0.2529},{"period":"1month","weight":-0.4904},{"period":"3month","weight":-0.6024},{"period":"6month","weight":-0.7286},{"period":"1year","weight":-0.8088},{"period":"ytd","weight":-0.5209}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.24176},{"month":2,"riseRate":0.3,"avgChangeRate":0.006803},{"month":3,"riseRate":0.4,"avgChangeRate":-0.056152},{"month":4,"riseRate":0.7,"avgChangeRate":0.09204},{"month":5,"riseRate":0.333333,"avgChangeRate":0.165831},{"month":6,"riseRate":0.3,"avgChangeRate":-0.040994},{"month":7,"riseRate":0.4,"avgChangeRate":-0.012797},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021406},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036238},{"month":10,"riseRate":0.1,"avgChangeRate":-0.217057},{"month":11,"riseRate":0.4,"avgChangeRate":0.056022},{"month":12,"riseRate":0.4,"avgChangeRate":0.005688}],"exchange":"NASDAQ","name":"Adaptimmune Therapeutics PLC","nameEN":"Adaptimmune Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptimmune Therapeutics PLC(ADAP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptimmune Therapeutics PLC,ADAP,Adaptimmune Therapeutics PLC股票,Adaptimmune Therapeutics PLC股票老虎,Adaptimmune Therapeutics PLC股票老虎国际,Adaptimmune Therapeutics PLC行情,Adaptimmune Therapeutics PLC股票行情,Adaptimmune Therapeutics PLC股价,Adaptimmune Therapeutics PLC股市,Adaptimmune Therapeutics PLC股票价格,Adaptimmune Therapeutics PLC股票交易,Adaptimmune Therapeutics PLC股票购买,Adaptimmune Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptimmune Therapeutics PLC(ADAP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction